Last reviewed · How we verify
Neoadjuvant and Adjuvant Immunotherapy
At a glance
| Generic name | Neoadjuvant and Adjuvant Immunotherapy |
|---|---|
| Sponsor | Xiwei XU |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer (PHASE3)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Exercise to Boost Response to Checkpoint Blockade Immunotherapy (NA)
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
- Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy (PHASE3)
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant and Adjuvant Immunotherapy CI brief — competitive landscape report
- Neoadjuvant and Adjuvant Immunotherapy updates RSS · CI watch RSS
- Xiwei XU portfolio CI